BRIEF—Chugai seeks new Kadcyla indication in Japan

The Roche unit Chugai has filed for an additional indication of Kadcyla (trastuzumab emtansine) as adjuvant therapy in patients with HER2-positive early breast cancer in Japan.

Yasushi Ito, Chugai’s executive vice president, co-head of project and lifecycle management unit, said: “There is still a high unmet medical need for the development of treatment methods when pathologic complete response is not obtained by neoadjuvant therapy. This application is the first step in providing patients with Kadcyla as a new treatment option of adjuvant therapy.

“Our HER2 franchise, consisting of Herceptin®, Perjeta® and Kadcyla has contributed to improving the outcomes of HER2-positive breast cancer. In this indication, we will continue to discuss with the regulatory authorities for the early approval of Kadcyla.”